Mortality in cancer patients with a history of cutaneous squamous cell carcinoma - a nationwide population-based cohort study

BMC Cancer

Research Article

Dóra Körmendiné Farkas¹  Annette Østergaard Jensen¹  Timothy L Lash¹  Sigrun Alba Johannesdottir¹  Anne Braae Olesen² 

[1] Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Allé 43-45, 8200, Aarhus N, Denmark;Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Allé 43-45, 8200, Aarhus N, Denmark;Department of Dermatology, Aarhus University Hospital, P.P. Ørumsgade 11, 8000, Aarhus C, Denmark;

关键词: Squamous Cell Carcinoma;    Basal Cell Carcinoma;    Charlson Comorbidity Index;    Squamous Cell Carcinoma Patient;    Cutaneous Squamous Cell Carcinoma;   

DOI  :  10.1186/1471-2407-12-126

 received in 2011-11-10, accepted in 2012-03-29,  发布年份 2012

来源: Springer

【 摘 要 】

BackgroundCutaneous squamous cell carcinoma (SCC) is associated with underlying immunosuppression, so it may be a prognostic marker in patients with subsequent cancer. We therefore conducted a nationwide population-based Danish cohort study to evaluate whether a history of cutaneuos SCC has prognostic impact in patients with one of the following index cancers: non-Hodgkin's lymphoma (NHL), or cancer of the lung, colon, rectum, breast, or prostate.MethodsWe used Danish medical databases, which cover the entire Danish population of 5.6 million inhabitants and linked them using the unique personal identification number assigned to all Danish residents. From 1982 through 2003, we identified 745 index cancer patients with and 79,143 without previous cutaneous SCC. Using Cox proportional hazards regression, we calculated adjusted mortality rate ratios (MRRs) with 95% confidence intervals (CIs).ResultsOverall, previous SCC was associated with an increased mortality of cancer (MRR 1.13, 95% CI: 1.04-1.23). When examining index cancers separately, increased MRRs were found for cancer of the lung (MRR 1.23, 95% CI: 1.05-1.43), colon (MRR 1.13, 95% CI: 0.92-1.40), rectum (MRR 1.29, 95% CI: 1.00-1.67), breast (MRR 1.09, 95% CI: 0.82-1.43), and NHL (MRR 1.09, 95% CI: 0.81-1.47), but not for prostate cancer (MRR 0.99, 95% CI: 0.83-1.18).ConclusionsOur results suggest that previous cutaneous SCC is associated with poor prognosis of some cancers. This finding stresses the importance of adherence to the existing recommendations of screening, diagnosis, and treatment of cancer in patients with a history of SCC.

【 授权许可】

CC BY   
© Johannesdottir et al; licensee BioMed Central Ltd. 2012